NASDAQ:NSTG - NanoString Technologies Stock Price, Forecast & News

NanoString Technologies trades on the NASDAQ under the ticker symbol "NSTG."

NanoString Technologies Inc (NASDAQ:NSTG) announced its quarterly earnings data on Monday, November, 4th. The biotechnology company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.54) by $0.10. The biotechnology company had revenue of $30.60 million for the quarter, compared to the consensus estimate of $28.05 million. NanoString Technologies had a negative net margin of 72.30% and a negative return on equity of 118.32%. View NanoString Technologies' Earnings History.

NanoString Technologies is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for NanoString Technologies.

NanoString Technologies issued an update on its FY 2019 Pre-Market earnings guidance on Monday, January, 13th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $125.7-125.7 million, compared to the consensus revenue estimate of $121.36 million.

2 equities research analysts have issued twelve-month price targets for NanoString Technologies' stock. Their forecasts range from $28.00 to $35.00. On average, they anticipate NanoString Technologies' share price to reach $31.50 in the next year. This suggests a possible upside of 12.0% from the stock's current price. View Analyst Price Targets for NanoString Technologies.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NanoString Technologies in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for NanoString Technologies.

Headlines about NSTG stock have been trending extremely negative recently, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. NanoString Technologies earned a media sentiment score of -4.5 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the near future. View News Stories for NanoString Technologies.

Some companies that are related to NanoString Technologies include Ablynx (ABLYF), Adaptive Biotechnologies (ADPT), Crispr Therapeutics (CRSP), Halozyme Therapeutics (HALO), Iovance Biotherapeutics (IOVA), Allogene Therapeutics (ALLO), Momenta Pharmaceuticals (MNTA), Acceleron Pharma (XLRN), Audentes Therapeutics (BOLD), Denali Therapeutics (DNLI), Fate Therapeutics (FATE), Alector (ALEC), Regenxbio (RGNX), Cortexyme (CRTX) and SpringWorks Therapeutics (SWTX).

Based on aggregate information from My MarketBeat watchlists, some companies that other NanoString Technologies investors own include CA (CA), BlackRock (BLK), Endologix (ELGX), Aegean Marine Petroleum Network (ANW), Chipotle Mexican Grill (CMG), Precision Drilling (PD), AutoZone (AZO), Designer Brands (DBI), Bank Of The Ozarks (OZRK) and Eaton Vance Floating-Rate Income Trust (EFT).

NanoString Technologies' stock is owned by many different of retail and institutional investors. Top institutional investors include Rhenman & Partners Asset Management AB (0.39%), Conestoga Capital Advisors LLC (0.06%) and Exchange Traded Concepts LLC (0.01%). Company insiders that own NanoString Technologies stock include Charles P Waite, Jr, David W Ghesquiere, J Chad Brown, K Thomas Bailey, Kirk Malloy, Lifesciences Ii LP Clarus, Mary Tedd Allen, Nicholas Galakatos, R Bradley Gray and William Young. View Institutional Ownership Trends for NanoString Technologies.

NSTG stock was sold by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB. Company insiders that have sold NanoString Technologies company stock in the last year include Charles P Waite, Jr, David W Ghesquiere, J Chad Brown, K Thomas Bailey, Kirk Malloy, Lifesciences Ii LP Clarus, Mary Tedd Allen, R Bradley Gray and William Young. View Insider Buying and Selling for NanoString Technologies.

NSTG stock was acquired by a variety of institutional investors in the last quarter, including Conestoga Capital Advisors LLC and Exchange Traded Concepts LLC. View Insider Buying and Selling for NanoString Technologies.

Shares of NSTG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NSTG stock can currently be purchased for approximately $28.12.

NanoString Technologies has a market capitalization of $1.01 billion and generates $106.73 million in revenue each year. The biotechnology company earns $-77,400,000.00 in net income (profit) each year or ($2.78) on an earnings per share basis. NanoString Technologies employs 476 workers across the globe.View Additional Information About NanoString Technologies.

The official website for NanoString Technologies is http://www.nanostring.com/.

NanoString Technologies' mailing address is 530 FAIRVIEW AVENUE NORTH SUITE 2000, SEATTLE WA, 98109. The biotechnology company can be reached via phone at 206-378-6266 or via email at [email protected]